Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)

Siegel CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Louis E, Sebastian S, Hebuterne X, Bell A, Soderman C, Schubert S, Atreya R, Polyak S, Hoque S, Krummenerl A, Bokemeyer B, Krummenerl T, Shulmann S, Karlen P, Moum B, Dolin P (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Book Volume: 11

Pages Range: S333-S334

Authors with CRIS profile

Involved external institutions

University of Oslo Norway (NO) Dr. Scott Shulman Canada (CA) Danderyds sjukhus Sweden (SE) Atlanta Gastroenterology Associates United States (USA) (US) Weston General Hospital United Kingdom (GB) Charité - Universitätsmedizin Berlin Germany (DE) University of Pennsylvania United States (USA) (US) University of Iowa United States (USA) (US) Hôpital l'Archet (CHU de Nice) France (FR) Centre Hospitalier Universitaire de Liège (CHU Liège) Belgium (BE) Hull and East Yorkshire Hospitals NHS Trust United Kingdom (GB) Capio S:t Görans sjukhus Sweden (SE) Barts Health NHS Trust United Kingdom (GB) Krankenhaus Martha-Maria Halle-Dölau Germany (DE) Gastroenterologische Gemeinschaftspraxis Minden Germany (DE) Dartmouth-Hitchcock Medical Center (DHMC) United States (USA) (US)

How to cite

APA:

Siegel, C.A., Lichtenstein, G., Siegmund, B., Lewis, J.D., Wolf, D., Louis, E.,... Dolin, P. (2017). Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02). (pp. S333-S334).

MLA:

Siegel, C. A., et al. "Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)." 2017. S333-S334.

BibTeX: Download